ramipril + empagliflozin + finerenone

This is a **triple combination therapy** comprising *ramipril* (an angiotensin-converting enzyme inhibitor), *empagliflozin* (a sodium-glucose cotransporter-2 [SGLT2] inhibitor), and *finerenone* (a nonsteroidal mineralocorticoid receptor antagonist). This combination targets **multiple pathways responsible for cardiorenal injury**: inhibition of the renin-angiotensin system (ramipril), SGLT2-mediated glucose and sodium reabsorption (empagliflozin), and aldosterone/mineralocorticoid receptor-mediated pro-fibrotic and pro-inflammatory activity (finerenone). Preclinical and emerging clinical evidence suggests that this triple therapy produces **additive or synergistic reductions in albuminuria, proteinuria, blood pressure, cardiovascular and renal fibrosis, and overall survival benefit**—especially in settings such as diabetic kidney disease, chronic kidney disease (CKD), and cardiorenal syndromes[1][2][3][5][9]. Each agent acts independently, and finerenone particularly addresses inflammation and fibrosis, empagliflozin acts on glucose and sodium homeostasis as well as hemodynamic stress, and ramipril blocks angiotensin II-mediated constrictive and fibrotic pathways.